P&G’s Lafley: Company delivered fiscal year commitments
CINCINNATI — Despite a challenging retail environment, Procter & Gamble delivered “top and bottom line commitments for the fiscal year,” said chairman, president, and CEO A.G. Lafley
For fiscal year 2014 core earnings per share of $4.22, an increase of 5% versus the prior year. Excluding the impact of foreign exchange, currency-neutral core earnings per share increased 14%. Diluted net earnings per share were $4.01, an increase of 4%. Organic sales grew 3%, driven by 3% unit volume growth. Net sales were $83.1 billion, an increase of 1% versus the prior year, including a negative two-percentage point impact from foreign exchange.
For the fourth quarter, core earnings per share were 95 cents, an increase of 20% versus the prior year period. Excluding the impact of foreign exchange, currency-neutral core earnings per share increased 25%. Diluted net earnings per share were 89 cents, an increase of 39% percent. Organic sales grew 2%, including a two-percentage point benefit from pricing. Shipment volume was in-line with prior year levels.
Net sales were $20.2 billion, a decrease of 1% versus the prior year period, including a negative two-percentage point impact from foreign exchange and a modest negative impact from minor divestitures, the company stated.
“We met our objectives in a very difficult operating environment, delivered strong constant currency earnings growth, and built on our strong track record of cash returns to shareholders. Still, we have more work to do to deliver the profitable sales growth and strong cash productivity we are capable of delivering. We will discuss our going-forward strategy and plans to further strengthen our results during our earnings call this morning,” Lafley stated.
For fiscal 2014, beauty segment organic sales were flat with gains from market growth and product and commercial innovation in hair care, deodorants and personal cleansing offset by sales decreases in salon professional and skin care from competitive activity and market contraction.
Grooming segment organic sales increased 3% due to higher pricing and innovation on blades and razors and appliances, which was partially offset by negative geographic and product mix from disproportionate growth in developing markets and disposables, P&G stated.
Behaviorial health kiosk debuts at retail-based health clinic in Philadelphia
PHILADELPHIA — The Department of Behavioral Health and Intellectual Disability Services, in conjunction with the Scattergood Behavioral Health Foundation, Screening for Mental Health and Family Practice and Counseling Network, are officially introducing on Aug. 5 the first Behavioral Health Screening Kiosk inside a retail-based health clinic in ShopRite in Philadelphia.
Developed through the 2014 Scattergood Design Challenge, the Behavioral Kiosk provides ShopRite and QCare Clinic customers with:
• An assessment of their mental health;
• Information on whether their mental health is consistent with a mental health disorder;
• An overview of the signs and symptoms of treatable mental health conditions; and
• Resources for quality treatment options including QCare staff.
The 2014 Scattergood Design Challenge began with Drexel University School of Public Health graduate students Gregory Caplan and Teresa Moore in July 2013, as part of their capstone Master’s project. After a collaborative agreement with FPCN to pilot the winning design, the two posed a question to a national audience that asked those interested to develop a desirable, impactful, viable and sustainable mental health component in a retail clinic. The aim of the project was to increase the awareness and reduce the stigma of mental health conditions by increasing access to quality care.
The Behavioral Health Kiosk was submitted by DBHIDS and SMH of Wellesley Hills, Mass. SMH, founded in 1991, has had more than 3 million people use their evidence based screening tool, including 460,000 in 2013 alone. The DBHIDS’ initiative Healthy Minds Philly was the development of this SMH screening tool using local Philadelphia resource and referral information.
Scattergood and DBHIDS/SMH have now brought this online tool to its first ever point of service location, QCare, while helping to integrate mental health into a retail clinic setting. QCare is operated by FPCN.
FDA approves Striverdi Respimat spray to treat COPD
SILVER SPRING, Md. — The Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray for the treatment of chronic obstructive pulmonary disease, including chronic bronchitis and/or in patients with emphysema that are experiencing airflow obstruction, the agency announced. The spray can be used once daily over a long length of time.
“The availability of this new long-term maintenance medication provides an additional treatment options for the millions of Americans who suffer with COPD,” said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research.
COPD is a lung disease that makes breathing difficult and becomes worse over time. Symptoms include wheezing, cough, chest tightness and shortness of breath. Cigarette smoking is the leading cause of the disease, the agency noted.
Striverdi Respimat is distributed by Boehringer Ingelheim Pharmaceuticals.